Project Grant R21AI188073
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$424K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
This $300,000 federal Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to engineer human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting NTPDase3 on B cells for controlling type 1 diabetes (T1D). The project, led by Sanford Research, will test CAR Tregs with varying antigen binding affinities to optimize their activation, proliferation, and suppressive function against islet-reactive T...
This $128,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of novel chimeric antigen receptor (CAR) T cell therapies to eliminate HIV reservoirs in non-human primate models. The goal is to engineer a second-generation anti-PD-1 CAR T cell therapy that can more specifically and safely deplete the pool of HIV-infected T follicular helper (Tfh) cells, which...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $231,131 to Duquesne University to develop and evaluate injectable 3D-clustered human fibroblastic reticular cells (clFRCs) for expanding regulatory T cells (Tregs) in allograft transplant applications. The key products to be delivered include: Optimized clFRC prototypes capable of generating Tregs in vitro by tuning...
This federal Project Grant award of $441,202 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research by the University of California, Berkeley to investigate the role of ex-regulatory T cells (ex-Tregs) in autoimmunity and cancer immunity. The research aims to understand how ex-Tregs, which arise from regulatory T cells (Tregs), can promote anti-cancer immunity and autoimmunity when...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,648,086 to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to conduct research on immune repertoire remodeling following B cell-targeted CAR T cells for the induction of renal allograft tolerance in non-human primates. The goal is to...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) program, provides $704,198 to Trustees of Dartmouth College to develop chimeric antigen receptor (CAR) T regulatory cells (Tregs) that are engineered to persist in the central nervous system (CNS) and target amyloid-beta aggregates in order to treat Alzheimer's disease. The award period runs from December 1, 2024 to November 30, 2026. The goal is to create CAR Tregs that can traffic to...
This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on enhancing the persistence of CD4CAR T-cell therapies to treat HIV infection. The $186,408 award will support research to characterize and overcome the inhibitory effects of soluble HIV antigen on CD4CAR T-cell function, as well as strategies to extend the persistence of these therapeutic T cells using the IL15...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $810,875 to The Trustees of the University of Pennsylvania to develop two novel chimeric antigen receptor (CAR) T cell strategies to selectively deplete autoantibody-secreting B cells as a potential curative treatment for acquired thrombotic thrombocytopenic purpura (ITTP), a life-threatening autoimmune disorder. The award aims to conduct in-depth preclinical...
This federal Project Grant award of $417,984 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research conducted by the Scripps Research Institute to identify small molecule compounds that can selectively induce the differentiation of functional regulatory T cells (Tregs). The research aims to address challenges in expanding Treg populations without causing unintended...